# Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

> **NCT05633446** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Gylden Pharma Ltd** · enrollment: 110 (estimated)

## Conditions studied

- Coronavirus
- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** PepGNP-COVID19 (One vaccination)
- **OTHER:** Water for injection (One vaccination)
- **BIOLOGICAL:** PepGNP-COVID19 (Two vaccinations)
- **OTHER:** Water for injection (Two vaccinations)

## Key facts

- **NCT ID:** NCT05633446
- **Lead sponsor:** Gylden Pharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05633446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05633446, "Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05633446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*